Pediatric Vaccine Market is projected to exceed US$ 48 Billion by the year 2024. Increasing government and non-government funding for the development of new vaccines, along with raising awareness about the benefits of vaccination, is certainly expected to positively drive the market growth in the coming years. In order to cut the healthcare expenses, governments have been making continuous efforts to reduce the cost of patient immunization through various vaccination programs funded by government or non-government health authorities. For example; several countries have included Children Vaccination Programs, which offers vaccines to children who lack health insurance or one who cannot afford the cost of vaccination.

Growing prevalence of chronic diseases is another major market driver, driving the market of infant (pediatric) vaccines. The immune system is not fully developed in infants, hence they are at a higher risk of contracting severe diseases and so, vaccination plays a significant role in their prevention. According to WHO; effective immunization activities have had a major impact on reducing measles deaths. It is found that measles vaccination prevented an estimated 20.4 million deaths across the globe. Global measles deaths have decreased by 84% from an estimated 550,100 in 2000 to 89,780 in 2016.

Renub Research report titled “Pediatric Vaccine Market, Global Forecast Infants Vaccinated, Vaccines Administered, Immunization, By Disease [Influenza, MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, and Combination Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Pediatric (Infants) Vaccine Market.

By Disease - Pneumococcal Vaccine is likely to grow at Noteworthy Rate in the Forthcoming Years
The report studies the market of the following vaccine: Influenza, MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, and Combination Vaccine. Pneumococcal and Combination Vaccines together hold the significant market share in pediatric (infants) vaccine market and is expected to continue so during the forecast period.

Nearly 650 Million Vaccines Doses will be administered in Pediatrics (Infants) by the year 2024
As per our analysis; it is estimated that by the year 2024, the doses of vaccines administered will reach nearly 650 Million. The number of vaccine doses is expected to grow considerably during the forecast period due to growing awareness among the parents about the benefits of vaccines and also the developing countries around the world that now have included a number of vaccines to their national immunization programme as per WHO recommendations, which indeed will drive the pediatric vaccine market in recent years.

Regional - Immunization Profile
The report also comprises of the en-detail study of global and regional immunization profile: By Diseases such as Measles, Mumps, Rubella, Diphtheria, Tetanus, Polio and so on and By Regions such as Africa (AFR), Americas (AMR), Eastern Mediterranean (EMR), Europe (EUR), South-East Asia (SEAR), Western Pacific (WPR) and Global.

Company Analysis
GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently in vaccine business globally. These companies have been studied thoroughly in the report.

Global Pediatric (Infants) Vaccine Market has been extensively studied from 3 major points:

1. Pediatrics Vaccines (Disease wise) Market & Forecast
2. Number of Vaccinated Pediatric (Infants) (Disease wise) & Forecast
3. Doses of Vaccines Administered in Pediatric (Infants) (Disease wise) & Forecast

This market research report provides a complete analysis of the Global Pediatric (Infants) Vaccine Market and their projections for the upcoming years, Growth Drivers, Challenges, and Disease wise number of reported cases.


By Disease

  • Influenza
  • MMR (Measles, Mumps, and Rubella)
  • Pneumonia
  • Meningitis
  • Hepatitis
  • Tap (Diphtheria, Tetanus, Pertussis)
  • Haemophilus influenzae type B
  • Polio
  • Rotavirus
  • Varicella
  • Combination Vaccine


Key Companies Covered in the Report

  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Pfizer